Biogen is buying anti-inflammatory drug startup RayThera for up to $1 billion

QuartzIndependentCenter3 days ago

Biogen has agreed to acquire RayThera, an anti-inflammatory drug startup, for up to $1 billion. The acquisition includes several small-molecule anti-inflammatory drug candidates, with the lead candidate expected to enter human trials this summer.

Bias read (Center): The article reports on a business transaction between two companies without taking a stance, using neutral language and providing factual information about the acquisition and its implications.